FORMULATION AND EVALUATION OF ANTIHYPERTENSIVE BILAYER TABLETAbstract
The present research work was carried out to Formulate and evaluation of bilayer tablet dosage form for the treatment of Hypertension. The objective of this study to compare the specific characteristics of Olmesartan Midoxomil [Angiotensin II receptor antagonist] and Hydrochlorothiazide [Thiazide Diuretics] in order to design stable formulation. It can be concluded that Olmesartan Midoxomil [Angiotensin II receptor antagonist] and Hydrochlorothiazide [Thiazide Diuretics] were successfully formulated in combination as a Bilayer tablet form with Croscarmellose sodium, Lactose monohydrate and microcrystalline cellulose PH101 for immediate release of both drugs. Both drugs were found to be stable in Bilayer tablet formulation and were found to be stable up to 6 months. This bilayer tablet dosage form increases the stability which may reduce loss and cost of formulation. It improves the benefits of producer, retailer, and patients. Recently, greater attention has been focused on development of bilayer tablet formulations. Over the past 30 years, the expenses and complications involved in marketing new drug entities have increased with concomitant recognition of therapeutic advantages of conventional drug delivery system. Several pharmaceutical companies are currently developing bi-layer tablets, for a variety of reasons: patent extension, efficient pharmacological effect, better patient compliance, etc. Bilayer tablet is becoming new approach for the successful drug delivery system and for better stability in combination. Bilayer tablets can be primary option to avoid chemical incompatibilities between APIs by physical separation.
D. G. Dnyaneshwar *, M. T. Deshmukh, R. S. Solunke and R. V. Shete
Rajgad Dnyanpeeth’s College of Pharmacy Bhor, Pune, Maharashtra, India.
18 July 2019
23 July 2019
10 September 2019
01 October 2019